Stockreport

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients [Seeking Alpha]

Structure Therapeutics Inc.  (GPCR) 
PDF Investing Group Leader Follow Summary Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight [Read more]